Cancer Treatment Centers of America, Atlanta, Grows Surgical Oncology Roster with Dr. Katherine Poruk

Article

In Partnership With:

Katherine Poruk, MD, a board-certified and fellowship-trained surgical oncologist and researcher, is the latest addition to the Cancer Treatment Centers of America®, Atlanta, physician team.

Katherine Poruk, MD, a board-certified and fellowship-trained surgical oncologist and researcher, is the latest addition to the Cancer Treatment Centers of America® (CTCA), Atlanta, physician team. Shewill focus on gastrointestinal and hepatopancreatic cancers, as well as sarcomas and melanomas.

Dr. Poruk earned her medical degree from the University of Utah School of Medicine in Salt Lake City and completed a general surgery residency at Johns Hopkins Hospital in Baltimore. She completed her fellowship in complex surgical oncology at Memorial Sloan-Kettering Institute in New York City.

“We’re thrilled that Dr. Poruk has chosen to join our team,” said Dr. Jeffrey Metts, chief of staff at CTCA® Atlanta. “Not only does her clinical background feature nationally renowned healthcare institutions, but her passion is also personal.”

The loss of her father to pancreatic cancer crystallized Dr. Poruk’s calling to oncology and has also shaped the way she practices medicine.

“My goal is to serve patients in a comprehensive and connected way,” said Dr. Poruk. “CTCA gives me that opportunity within a specialty hospital that is collaborative, innovative and compassionate.”

Dr. Poruk is a member of several organizations, including the Society of Surgical Oncology, American Association of Cancer Research, American College of Surgeons, Americas Hepato-Pancreato-Biliary Association and Association of Academic Surgery. She has also authored several publications, abstracts and book chapters.

About Cancer Treatment Centers of America

Cancer Treatment Centers of America® (CTCA) is a national oncology network of hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship. CTCA® publishes treatment results annually including patient experience, length of life, quality of life, patient safety and quality of care. CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research. CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country. Visit cancercenter.com for more information.

Related Videos
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Jasmin M. Zain, MD
Richard Kim, MD, an expert on colorectal cancer
A panel of 6 experts on colorectal cancer
Daneng Li, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.